Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia

Int J Neuropsychopharmacol. 2004 Dec;7(4):495-500. doi: 10.1017/S1461145704004419. Epub 2004 May 20.

Abstract

The association between the quinone oxidoreductase gene (NQO1) polymorphism (609C/T) and schizophrenia was examined to replicate and extend the findings of a previous study (Hori et al., 2003). The study sample was 107 schizophrenia in-patients and 106 healthy controls. The distributions of the NQO1 genotypes and alleles were not different between the schizophrenia patients and the controls. However, the frequency of the variant genotype was significantly higher in the subgroup with tardive dyskinesia (TD) than in the subgroup without (p=0.019). The subjects with allele T were significantly more frequent in the TD patients than in those without (odds ratio 2.256, 95% confidence interval 1.235-4.133). In addition, the Abnormal Involuntary Movement Scale (AIMS) score was significantly higher in the variant genotype group (T/T) than in other genotypic groups (C/C and C/T) (p=0.004). This study suggests that the NQO1 gene polymorphism (609C/T) may confer susceptibility to the development of TD in schizophrenia, at least in the Korean population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alleles
  • Antipsychotic Agents / adverse effects*
  • Case-Control Studies
  • Dyskinesia, Drug-Induced / epidemiology
  • Dyskinesia, Drug-Induced / genetics*
  • Female
  • Gene Frequency
  • Genotype
  • Humans
  • Korea / epidemiology
  • Male
  • Middle Aged
  • NAD(P)H Dehydrogenase (Quinone) / genetics*
  • Polymorphism, Genetic / genetics*
  • Psychiatric Status Rating Scales
  • Reverse Transcriptase Polymerase Chain Reaction
  • Schizophrenia / complications*
  • Schizophrenia / epidemiology
  • Schizophrenia / genetics*

Substances

  • Antipsychotic Agents
  • NAD(P)H Dehydrogenase (Quinone)
  • NQO1 protein, human